A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm
Tóm tắt
Evaluating the effect of convalescent plasma (CP) on some cytokine storm indices in severe COVID-19 patients. Totally, 62 patients were randomly assigned into two groups for this clinical trial. Patients in the intervention group received one unit (500 mL) plasma on the admission day plus standard drugs while the controls merely received standard treatments. Eventually, primary and secondary outcomes were evaluated. In the CP group, compared with controls, the mean levels of lymphocytes and IL-10 significantly increased while the levels of IL-6, TNF-α, and IFN-γ decreased (p < 0.05). The length of in-hospital stay, and mortality rate did not significantly reduce in the CP group compared with controls (p > 0.05) while WHO severity scores remarkably improved (p = 0.01), despite the higher frequency of underlying diseases among the CP group (66.7%) vs. controls (33.3%). Although CP has a remarkable immunomodulatory and antiviral potential to improve the cytokine storm and disease severity in COVID-19 patients, it did not considerably affect the mortality rate.
Tài liệu tham khảo
Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet 395:497–506
Han H, Ma Q, Li C et al (2020) Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect 9(1):1123–1130
Chen L, Liu HG, Liu W et al (2020) Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 43:E005
Xu Z, Shi L, Wang Y et al (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. https://doi.org/10.1016/S2213-2600(20)30076-X
Channappanavar R, Perlman S (2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39:529–539
Wang Z, Yang B, Li Q et al (2020) Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 71(15):769–777
Chen G, Wu D, Guo W et al (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130:2620–2629
Michot JM, Albiges L, Chaput N et al (2020) Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol 31:961–964
Zhang X, Song K, Tong F et al (2020) First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv 4:1307–1310
Odievre MH, de Marcellus C, Le Ducou Pointe H et al (2020) Dramatic improvement after tocilizumab of a severe COVID-19 in a child with sickle cell disease and acute chest syndrome. Am J Hematol. https://doi.org/10.1002/ajh.25855
Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507–513
Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan China. JAMA 323:1061–1069
Lenzer J (2020) Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ 369:m1335
World Health Organization. Coronavirus Disease 2019(COVID-19) Situation Report-41: Data as Reported by 10AM CET 01 March 2020. Available online at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200301-sitrep-41-covid-19.pdf?sfvrsn=6768306d_2.
Tang Y, Liu J, Zhang D et al (2020) Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol 11:1708
Rieder M, Wengenmayer T, Staudacher D et al (2020) Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation. Crit Care 24:435. https://doi.org/10.1186/s13054-020-03130-y
Tan W, Li S, Yiyang C et al (2020) Clinical efficacy analysis of 50 cases of corona virus disease 2019 in traditional Chinese medicine. Jilin J Chin Med 40:281–285
Kai-tao Y, Ming-yu L, Xin L et al (2020) Retrospective clinical analysis on treatment of novel coronavirus-infected pneumonia with traditional Chinese medicine Lianhua Qingwen. Chin J Exp Tradition Med Formul 26:8–12
Hou L, Huang H (2016) Immune suppressive properties of artemisinin family drugs. Pharmacol Therap 166:123–127
Mair-Jenkins J, Saavedra-Campos M, Baillie JK et al (2015) The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211:80–90
Planitzer CB, Modrof J, Kreil TR (2007) West Nile virus neutralization by US plasma-derived immunoglobulin products. J Infect Dis 196:435–440
Rojas M, Monsalve DM, Pacheco Y et al (2020) Ebola virus disease: An emerging and re-emerging viral threat. J Autoimmun 106:102375
Garraud O, Heshmati F, Pozzetto B et al (2016) Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol 23:39–44
Li L, Zhang W, Hu Y et al (2020) Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 324(5):460–470
Abolghasemi H, Eshghi P, Cheraghali AM et al (2020) Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfus Apher Sci. 59(5):102875
Duan K, Liu B, Li C et al (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. ProcNatl Acad Sci. 117(17):9490–9496
Gharbharan A, Jordans CCE, GeurtsvanKessel C et al (2020) Convalescent plasma for COVID-19. A randomized clinical trial. MedRxiv. https://doi.org/10.1101/2020.07.01.20139857
Salazar E, Perez KK, Ashraf M et al (2020) Treatment of COVID-19 patients with convalescent plasma. Am J Pathol 190(8):1680–1690
Hegerova L, Gooley T, Sweerus KA, Maree CL, Bailey N, Bailey M et al (2020) (2020) Use of convalescent plasma in hospitalized patients with covid-19—case series. Blood 136(6):759–762
Xia X, Li K, Wu L et al (2020) Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion. Blood 136(6):755–759
Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM et al (2020) Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 7(7):013600
Benjamin RJ, McLaughlin LS (2012) Plasma components: properties, differences, and uses. Transfusion 52(Suppl. 1):9S-19S
Lunemann JD, Nimmerjahn F, Dalakas MC (2015) Intravenous immunoglobulin in neurology–mode of action and clinical efficacy. Nat Rev Neurol 11:80–89
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P (2020) Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. https://doi.org/10.1136/bmj.m3939
Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C et al (2020) A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 24:NEJMoa2031304
Choghakabodi PM, Pouladzadeh M, Haybar H et al (2020) Biological whistleblowers for silent myocardial ischemia: diagnostic and prognostic approach. Recenti Prog Med 111(7):415–425
Hung IFN, Toe KKW, Lee C-K et al (2013) Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection. Chest 144(2):464–473
Hung IF, To KK, Lee C-K et al (2011) Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52(4):447–456
Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382(17):e38
Magro G (2020) Cytokine storm: is it the only major death factor in COVID-19 patients? Coagul role Med Hypotheses 142:109829